---
title: "SpyGlass Pharma, Inc. (SGP.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/SGP.US/overview.md"
symbol: "SGP.US"
name: "SpyGlass Pharma, Inc."
parent: "https://longbridge.com/zh-HK/quote/SGP.US.md"
datetime: "2026-04-15T03:09:00.666Z"
locales:
  - [en](https://longbridge.com/en/quote/SGP.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SGP.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SGP.US/overview.md)
---

# SpyGlass Pharma, Inc. (SGP.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 制藥 |
| 交易所 | US Market |
| 地址 | 27061 Aliso Creek Road, Suite 100, Aliso Viejo, California, United States |
| 官網 | [www.spyglasspharma.com](https://www.spyglasspharma.com) |

## 公司簡介

SpyGlass Pharma, Inc. 是一家生物制藥公司，專注于為患有慢性眼部疾病的患者提供治療和藥物輸送。該公司開發了 Bimatoprost 藥物墊-IOL 系統（BIM-IOL 系統），該系統由新型的專有藥物墊和一種眼內鏡片（IOL）組成，旨在在常規白內障手術中植入，以降低患者的眼內壓（IOP）。此外，它還開發了一種非 IOL 基礎的環形緩釋植入物，含有比馬前列素

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Malik Y. Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman |
| Patrick H. Mooney | CEO & Director |
| Chetan Pujara | Chief Research & Development Officer |
| Glenn Sussman | Co-founder & Chief Technology Advisor |
| Jean-Frederic Viret | Chief Financial Officer |
| Zachary Scheiner | Independent Director |
| Bilal Arshad Khan | Independent Director |
| Elizabeth G. O’Farrell | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| RA Capital Management, L.P. | 24.00% | 2026-02-09 |
| New Enterprise Associates, Inc. | 22.12% | 2026-02-13 |
| Vensana Capital Management, LLC | 9.90% | 2026-02-09 |
| Sands Capital Ventures, LLC | 7.48% | 2026-02-06 |
| Gilde Healthcare Partners B.V. | 6.54% | 2026-02-09 |
| Samsara BioCapital LLC | 6.31% | 2026-02-09 |
| Malik Y. Kahook | 2.61% | 2026-02-06 |
| Franklin Resources, Inc. | 0.90% | 2026-02-28 |
| Bilal Khan | 0.83% | 2026-02-09 |
| Patrick Mooney | 0.55% | 2026-02-06 |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**